Studies follow-up treatments after bone-building drugs in postmenopausal women with osteoporosis
Observes which medicines follow bone-building injections in women with severe bone thinning.
Plain-language title generated from the registry record
Registry title: Sequential Therapies After Osteoanabolic Treatment
Key facts
- Where
- Milan, Roma, Siena, and Udine, ItalySee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT06164795, who can take part
Where in Italy
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- Campus Bio-Medico UniversityRoma, ItalyTaking people
- Department of Medicine, Surgery and Neurosciences, University of SienaSiena, ItalyTaking people
- University-Hospital S. Maria della MisericordiaUdine, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- 424 General Military Hospital
- Trial code
- NCT06164795
- Record updated
- 22 July 2026
- Original description
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolicsRead full original descriptionShow less
Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics
Inclusion: Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide.
Exclusion: use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study; a bone disease other than postmenopausal osteoporosis; liver failure; any type of cancer; uncontrolled endocrine diseases; hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients; creatinine clearance <60 mL/min/1.73 m2; serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L).